Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
ValiRx PLC - Nuneaton, England-based drug development company - Appoints Catherine Tralau-Stewart as interim chief scientific officer. Says she has experience working across leading pharmaceutical companies and academic groups. Tralau-Stewart will review new, incoming science; enhance the progress of existing projects; and influence the overall strategic scientific direction of the company, ValiRx adds. Chief Executive Suzy Dilly comments: ‘I'm looking forward to having another in-house scientist with whom to share ideas and to develop and deliver upon our strategic ambitions. Cathy's wealth of experience in exactly the areas in which we wish to progress, makes her an excellent choice for this role.’
Current stock price: 16.61 pence, up 24% in London on Thursday
12-month change: down 25%
Copyright 2022 Alliance News Limited. All Rights Reserved.